EGFR mutation, CNS metastasis, AZD3759, lung cancer, first-line setting
Leptomeningeal metastases, Osimertinib resistance, macrophage, Midkine, Cerebrospinal fluid
non-small cell lung cancer, lorlatinib, ALK-positive, first-line treatment, Patient-centric trial